Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sanofi New Results From Rilzabrutinib Phase 2 Study Show Potential To Be First Advanced Oral Treatment For Moderate-To-Severe Asthma; Data Shows Rilzabrutinib Led To Numerical Reduction In Loss Of Asthma Control Events, Improvement In Symptoms And Was Well-Tolerated With No New Safety Signals Observed; Results Support The Further Development And Advancement Into A Phase 3 Program

Author: Benzinga Newsdesk | May 22, 2024 01:16pm

- Reuters

Posted In: SNY

06/28/2024 Malibu Boats, Inc. (MBUU)

07/01/2024 Equinix, Inc. (EQIX)

07/02/2024 Intel Corporation (INTC)

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

AnaptysBio Inc (ANAB)